Recognition in journals doesn't translate to recognition in practice
A condition affecting perhaps one in eight older adults hospitalized with heart failure goes largely unseen not for lack of treatment, but for lack of recognition. The TTRANSLATE-ATTR trial, enrolling hospitals across the United States, asks a deceptively simple question: can teaching physicians to look for something change how often they find it? In an era of medical complexity, the trial reminds us that knowledge embedded in practice—not merely in literature—is what reaches patients.
- ATTR-CM silently affects up to 13% of older hospitalized heart failure patients, yet most leave the hospital without ever receiving the diagnosis.
- The gap is not a mystery of science but a failure of clinical habit—doctors must first think to look before they can find.
- The TTRANSLATE-ATTR trial is randomizing entire hospitals, embedding expert coaching and diagnostic algorithms directly into existing workflows at more than 800 sites.
- Researchers will measure not just whether more tests are ordered, but whether more patients actually receive confirmed diagnoses—a critical distinction.
- If the intervention succeeds, a scalable model for closing diagnostic gaps could be adopted across the broader Get With The Guidelines network nationwide.
A heart condition called transthyretin amyloid cardiomyopathy, or ATTR-CM, affects up to 13 percent of older adults hospitalized with heart failure—yet most of those patients are never identified. The condition is treatable when caught, but catching it requires physicians to think to look for it, and in the busy routines of hospital care, many do not.
To address this, the American Heart Association has launched the TTRANSLATE-ATTR trial, a study that randomizes not individual patients but entire hospitals. Institutions enrolled in the Association's Get With The Guidelines network—more than 800 sites—are assigned either to standard care or to a structured educational intervention. That intervention includes tailored feedback on current diagnostic rates, expert coaching on ATTR-CM recognition, and diagnostic algorithms designed to fit naturally into existing clinical workflows.
The aim is not to add burden but to make the right diagnosis easier to remember and act upon. UCLA cardiologist Gregg Fonarow described the study as testing, in a rigorous and practical way, whether targeted education can close persistent gaps in recognition. Statisticians at the Duke Clinical Research Institute will compare diagnostic testing rates and confirmed diagnoses between intervention and control hospitals before and after the educational push.
The distinction between ordering a test and following through to a confirmed diagnosis is central to the trial's design—and to its ambitions. If the approach works, it could offer a scalable model for improving detection of a condition that, once identified, can be managed with newer therapies that slow progression and reduce hospitalizations. Funded by AstraZeneca but overseen by the American Heart Association with independent analysis by Duke, the trial's findings will be published and presented publicly, whatever the outcome.
A heart condition that silently affects one in every eight older adults admitted to the hospital with heart failure remains largely invisible to the doctors treating them. Transthyretin amyloid cardiomyopathy, or ATTR-CM, is increasingly recognized in medical literature but persistently missed in the rooms where patients actually receive care. The American Heart Association's latest statistics underscore the gap: up to 13 percent of older hospitalized patients with heart failure and preserved ejection fraction carry this diagnosis, yet most never get identified.
The condition is treatable when caught. But catching it requires doctors to think to look for it—and many don't. So the American Heart Association has launched a trial designed to test whether the simple act of teaching physicians better can change what they do. The study, called TTRANSLATE-ATTR, is enrolling hospitals across the country that participate in the Association's Get With The Guidelines quality improvement program, a network of more than 800 institutions. Rather than randomizing individual patients, researchers are randomizing entire hospitals: some will receive standard care, others will get a structured educational intervention woven directly into their existing workflows.
The intervention itself is practical. Participating hospitals in the intervention group will receive tailored feedback on their current diagnostic rates, expert-led coaching on ATTR-CM recognition, and diagnostic algorithms designed to fit into the routines doctors already follow. The goal is not to add burden but to make diagnosis easier to remember and execute. Gregg Fonarow, a cardiologist at UCLA and a steering committee member, described the approach as testing "in a rigorous and practical way, whether targeted clinician education can help close persistent gaps in the recognition of ATTR-CM in hospitalized patients with heart failure." By embedding the trial within existing hospital infrastructure rather than creating a separate research apparatus, the study can measure real-world impact.
The trial will track whether these interventions actually move the needle. Statisticians at the Duke Clinical Research Institute will analyze site-level rates of diagnostic testing and confirmed diagnoses before and after the educational push, comparing intervention hospitals to control hospitals. The design allows researchers to see not just whether more patients get tested, but whether more actually receive a confirmed diagnosis—a distinction that matters. It's one thing to order a test; it's another to follow through and act on the result.
If the intervention works, the implications could be substantial. Success would suggest that a scalable, evidence-based approach to clinician education can improve detection of a treatable condition across a large network of hospitals. That matters because ATTR-CM, once diagnosed, can be managed with newer therapies that slow disease progression and reduce hospitalizations. The undiagnosed patients currently hospitalized with heart failure may be missing the chance for earlier intervention. Fonarow emphasized that the goal extends beyond simply proving the intervention works: "The goal is not only to understand whether this approach works, but also how it might be scaled responsibly if the findings support broader adoption."
The trial is funded by AstraZeneca, a pharmaceutical company with a stake in ATTR-CM diagnosis and treatment, but the American Heart Association maintains oversight of study execution and data governance, while the Duke Clinical Research Institute conducts independent analysis. Results will be published in scientific journals and presented at national cardiology meetings, making the findings available to the broader medical community regardless of outcome. Whether structured education can close the diagnostic gap remains an open question—but the trial is designed to answer it with the rigor that real-world hospital settings demand.
Citações Notáveis
This study is designed to test, in a rigorous and practical way, whether targeted clinician education can help close persistent gaps in the recognition of ATTR-CM in hospitalized patients with heart failure.— Gregg C. Fonarow, M.D., UCLA Cardiomyopathy Center and trial steering committee member
The goal is not only to understand whether this approach works, but also how it might be scaled responsibly if the findings support broader adoption.— Gregg C. Fonarow
A Conversa do Hearth Outra perspectiva sobre a história
Why does a condition affecting one in eight older heart failure patients remain so underdiagnosed if it's increasingly recognized in the literature?
Recognition in journals doesn't automatically translate to recognition in practice. Doctors are overwhelmed, protocols are entrenched, and ATTR-CM isn't yet reflexive thinking for most cardiologists. It takes deliberate effort to change what gets tested.
So this trial is betting that education alone can shift clinical behavior?
Not education alone—education embedded in workflow. There's a difference. They're not asking doctors to attend a conference. They're putting diagnostic tools and feedback directly into the systems where decisions happen.
What happens if the intervention doesn't improve diagnosis rates?
That's valuable too. It would suggest that the barrier isn't knowledge but something else—maybe access to testing, maybe reimbursement, maybe skepticism about the diagnosis itself. You learn where the real friction is.
Why randomize hospitals instead of individual patients?
Because you're testing a system-level intervention, not a drug. You want to know if changing hospital culture and workflow changes practice. Individual randomization wouldn't capture that effect.
If this works, what's the timeline for rolling it out nationally?
That's the question Fonarow raised—how to scale responsibly. Success in a trial doesn't automatically mean success everywhere. Different hospitals have different cultures, resources, and patient populations. The trial will generate insights on implementation, not just efficacy.
Who benefits most if diagnosis improves?
The patients who are currently hospitalized, treated for heart failure, and sent home still carrying an undiagnosed, progressive condition. They're the ones missing the window for earlier intervention with therapies that actually slow the disease.